News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
January, 2025
January 2025
M T W T F S S
 12345
6789101112
13141516171819
20212223242526
2728293031  
SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond
SPCC/LinkedIn
Jan 21, 2025, 06:43

SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond

SPCC (Sharing Progress in Cancer Care) shared the following on LinkedIn:

“HR+/HER2- MBC treatment landscape: what’s next? Join our upcoming expert-led webinar on 29 January 2025 at 18:00 CET.

Discussant: Miguel Martin (ES)

Experts: Patrick Neven (BE), Joyce O’Shaughnessy (US)

Key topics:

  • Latest HR+ HER2- MBC data and future treatment landscape
  • Biomarker testing
  • Biomarker vs non-biomarker driven treatment choices
  • Sequencing therapies: current and future approaches tailored to clinical characteristics

Register here (free of charge).

This webinar is supported by an unrestricted educational grant from Eli Lilly.”

SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond

biomarker testing cancer Cancer research cancer therapy cancer treatment advancements clinical characteristics Eli Lilly HR+/HER2- MBC Joyce O'Shaughnessy metastatic breast cancer Miguel Martin OncoDaily Oncology Patrick Neven sequencing therapies
Special Coverage
Blog
Jan 21, 2025, 06:43
SPCC: Outlook for the HR+/HER2- MBC treatment landscape in 2025 and beyond
Blog
Jan 21, 2025, 06:35
Leading experts reviewing practice-changing publications in HCC and stage III melanoma - ESMO
Blog
Jan 21, 2025, 06:28
ASCO Thanks Drs. Bertagnolli, Rathmell for Their Service Leading NIH, NCI
Career
Jan 21, 2025, 06:24
Justin Taylor was elected to the ASCI - Sylvester Comprehensive Cancer Center
Insight
Jan 21, 2025, 06:22
Biological and clinical significance of tumour-infiltrating lymphocytes in the era of immunotherapy
Insight
Jan 21, 2025, 06:17
Fabio Moraes: Global linear accelerator requirements and personalised country recommendations
Blog
Jan 21, 2025, 06:15
Petros Grivas: Excited for our 12th Immune-related Adverse Events panel CME series
Blog
Jan 21, 2025, 05:44
Aruni Ghose: Collaboration with Dr. Swarupa Mitra on innovative cancer care
Blog
Jan 21, 2025, 05:12
Intratumoral, pembrolizumab and mRNA-2752 for high-risk Ductal Carcinoma In Situ
Blog
Jan 21, 2025, 05:10
Mark Lawler: The severe cancer workforce crisis - a ticking time bomb that must be diffused to avert a cancer crisis
Blog
Jan 21, 2025, 04:58
The 2025 American Cancer Society Cancer Statistics report
Blog
Jan 21, 2025, 04:55
ASCO applauds Dr. Monica M. Bertagnolli and Dr. Kimryn Rathmell for their exceptional leadership and dedication at NIH and NCI